Back
Zymeworks, Inc. 10K Form
Buy
72
ZYME
Zymeworks, Inc.
Last Price:
$26.45
Seasonality Move:
-4.63%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2020-08-05 | 10Q | ZYME/Zymeworks, Inc. Quarterly |
| 2020-05-07 | 10Q | ZYME/Zymeworks, Inc. Quarterly |
| 2020-03-02 | 10K | ZYME/Zymeworks, Inc. Annual |
| 2019-11-05 | 10Q | ZYME/Zymeworks, Inc. Quarterly |
| 2019-08-02 | 10Q | ZYME/Zymeworks, Inc. Quarterly |
| 2019-05-02 | 10Q | ZYME/Zymeworks, Inc. Quarterly |
Receive ZYME News And Ratings
See the #1 stock for the next 7 days that we like better than ZYME
ZYME Financial Statistics
Sales & Book Value
| Annual Sales: | $76.3M |
|---|---|
| Cash Flow: | $-32.3M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $4.23 |
| Price / Book: | 6.18 |
Profitability
| EPS (TTM): | -0.84690 |
|---|---|
| Net Income (TTM): | $-63.4M |
| Gross Margin: | $65.1M |
| Return on Equity: | -18.82% |
| Return on Assets: | -14.54% |
Zymeworks, Inc. Earnings Forecast
Key Zymeworks, Inc. Financial Ratios
-
The Gross Profit Margin over the past 11 years for ZYME is 85.33%.
-
The Selling, General & Administrative Expenses for ZYME have been equal to 80.61% of Gross Profit Margin.
-
The Research & Development expenses have been 176.43% of Revenue.
-
The Net Earning history of ZYME is -160.80% of Total Revenues.
-
Per Share Earnings over the last 11 years have been positive in 4 years.
Zymeworks, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ZYME |
| CUSIP: | 98985W |
| Website: | zymeworks.com |
Debt
| Debt-to-Equity Ratio: | 0.06 |
|---|---|
| Current Ratio: | 6.94 |
| Quick Ratio: | 6.69 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 176.89 |
ZYME Technical Analysis vs Fundamental Analysis
Buy
72
Zymeworks, Inc. (ZYME)
is a Buy
Is Zymeworks, Inc. a Buy or a Sell?
-
Zymeworks, Inc. stock is rated a BuyThe current Zymeworks, Inc. [ZYME] share price is $26.22. The Score for ZYME is 72, which is 44% above its historic median score of 50, and infers lower risk than normal.